These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 28473214)

  • 41. Fracture risk associated with common medications used in treating type 2 diabetes mellitus.
    Wolverton D; Blair MM
    Am J Health Syst Pharm; 2017 Aug; 74(15):1143-1151. PubMed ID: 28743778
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of EMPA-REG OUTCOME
    Naing S; Poliyedath A; Khandelwal S; Sigala T
    Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016; 9(2):229-40. PubMed ID: 26589238
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users.
    Gamble JM; Thomas JM; Twells LK; Midodzi WK; Majumdar SR
    Medicine (Baltimore); 2016 Jun; 95(26):e3995. PubMed ID: 27368005
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.
    Yang JY; Moon AM; Kim H; Pate V; Barritt AS; Crowley MJ; Buse JB; Stürmer T; Alexopoulos AS
    J Diabetes Complications; 2020 Nov; 34(11):107706. PubMed ID: 32843283
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.
    Davidson MH
    Postgrad Med; 2014 May; 126(3):56-65. PubMed ID: 24918792
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus.
    Kim CH; Hwang IC; Choi HM; Ahn CH; Yoon YE; Cho GY
    Int J Cardiol; 2022 Oct; 364():104-111. PubMed ID: 35716949
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular effects of anti-diabetes drugs.
    Younk LM; Lamos EM; Davis SN
    Expert Opin Drug Saf; 2016 Sep; 15(9):1239-57. PubMed ID: 27268470
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Not Available].
    Toft E; Rydén M
    Lakartidningen; 2018 Feb; 115():. PubMed ID: 29461566
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease.
    Dihoum A; Rena G; Pearson ER; Lang CC; Mordi IR
    Expert Opin Investig Drugs; 2023 Apr; 32(4):291-299. PubMed ID: 36972373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors.
    Bistola V; Lambadiari V; Dimitriadis G; Ioannidis I; Makrilakis K; Tentolouris N; Tsapas A; Parissis J
    Heart Fail Rev; 2018 May; 23(3):377-388. PubMed ID: 29383638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beyond glycemic control: treating the entire type 2 diabetes disorder.
    Brunton S
    Postgrad Med; 2009 Sep; 121(5):68-81. PubMed ID: 19820276
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sweet and simple as syrup: A review and guidance for use of novel antihyperglycemic agents for post-transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation.
    Lawrence SE; Chandran MM; Park JM; Sweiss H; Jensen T; Choksi P; Crowther B
    Clin Transplant; 2023 Mar; 37(3):e14922. PubMed ID: 36708369
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overview of the cardiovascular benefit with diabetic agents and novel combination products for type 2 diabetes.
    Morello CM
    Am J Manag Care; 2017 Aug; 23(13 Suppl):S241-S246. PubMed ID: 28978218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes.
    Cattadori G; Pantanetti P; Ambrosio G
    Diabetes Res Clin Pract; 2019 Nov; 157():107835. PubMed ID: 31479706
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.